|
Cayman Islands
(州或其他管轄範圍
成立公司或組織) |
| |
2834
(主要標準工業
分類代碼號) |
| |
Not Applicable
(I.R.S. Employer
識別碼) |
|
|
Portia Ku, Esq.
Vincent Lin, Esq. O’Melveny & Myers LLP Times Square Tower 7 Times Square New York, NY 10036 +1-212-326-2000 |
| |
Yu-Hsin Lin
Belite Bio, Inc 5820 Oberlin Drive, Suite 101, San Diego, CA 92121 +1-858-246-6240 |
| |
Richard Anslow, Esq.
John J. Hart, Esq. Ellenoff Grossman&Schole LLP 1345 Avenue of the Americas, 11th Floor New York, New York 10105 +1-212-370-1300 |
|
|
Prospectus Summary
|
| | | | 1 | | |
|
Risk Factors
|
| | | | 17 | | |
|
有關前瞻性陳述的特別説明
|
| | | | 86 | | |
|
Use of Proceeds
|
| | | | 88 | | |
|
Dividend Policy
|
| | | | 89 | | |
|
Capitalization
|
| | | | 90 | | |
|
Dilution
|
| | | | 92 | | |
|
民事責任的可執行性
|
| | | | 94 | | |
|
公司歷史和結構
|
| | | | 96 | | |
|
選定的合併財務數據
|
| | | | 97 | | |
|
管理層對財務狀況和經營成果的討論和分析
|
| | | | 98 | | |
|
Business
|
| | | | 112 | | |
|
Regulations
|
| | | | 138 | | |
|
Management
|
| | | | 167 | | |
|
主要股東
|
| | | | 176 | | |
|
關聯方交易
|
| | | | 178 | | |
|
股本説明
|
| | | | 183 | | |
|
美國存托股份説明
|
| | | | 195 | | |
|
有資格未來出售的股票
|
| | | | 205 | | |
|
Taxation
|
| | | | 207 | | |
|
Underwriting
|
| | | | 212 | | |
|
與此產品相關的費用
|
| | | | 223 | | |
|
Legal Matters
|
| | | | 224 | | |
|
Experts
|
| | | | 225 | | |
|
在哪裏可以找到更多信息
|
| | | | 226 | | |
|
合併財務報表索引
|
| | | | F-1 | | |
Indication
|
| |
Clinical Trials
|
| |
Trial Participants
|
| |
Estimated Timeline
|
|
STGD1 | | | 第一階段單次和多次遞增劑量試驗 | | | Healthy adult subjects | | | Completed | |
| | | Phase 1b trial | | | 患有STGD1的青少年患者 | | | Completed | |
| | | Phase 2 trial | | | 患有STGD1的青少年患者 | | | 正在進行,預計將在12、15、18和21個月捕獲臨時數據讀出,並在24個月捕獲最終數據讀出。 | |
| | | Phase 3 trial | | | 患有STGD1的青少年患者 | | | Initiated | |
Dry AMD | | | 第一階段單次遞增劑量試驗 | | | Healthy adult subjects | | | Completed | |
| | | Phase 2 or Phase 3 trial | | |
Patients with dry AMD
|
| | 2022 | |
| | |
For the Years Ended
December 31, |
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
| | |
(amounts in $ and in thousands,
除股票和每股數據外) |
| |||||||||
Expenses | | | | | | | | | | | | | |
Research and development
|
| | | | 3,688 | | | | | | 7,419 | | |
一般和行政
|
| | | | 2,055 | | | | | | 2,378 | | |
Total operating expenses
|
| | | | 5,743 | | | | | | 9,797 | | |
Loss from operations
|
| | | | (5,743) | | | | | | (9,797) | | |
Other income (expense): | | | | | | | | | | | | | |
Interest income
|
| | | | 12 | | | | | | 5 | | |
Interest expense
|
| | | | (21) | | | | | | — | | |
Other income
|
| | | | — | | | | | | 126 | | |
Total other (expense) income, net
|
| | | | (9) | | | | | | 131 | | |
Loss before income tax
|
| | | | (5,752) | | | | | | (9,666) | | |
Income tax expense
|
| | | | (1) | | | | | | — | | |
Net loss
|
| | | | (5,753) | | | | | | (9,666) | | |
其他綜合收益(虧損) | | | | | | | | | | | | | |
外幣折算調整,扣除零税
|
| | | | 6 | | | | | | (152) | | |
Total comprehensive loss
|
| | | $ | (5,747) | | | | | $ | (9,818) | | |
計算中使用的普通股加權平均數: | | | | | | | | | | | | | |
—Basic and Diluted
|
| | | | 8,790,397 | | | | | | 9,569,932 | | |
每股普通股淨虧損 | | | | | | | | | | | | | |
—Basic and Diluted
|
| | | $ | (0.65) | | | | | $ | (1.01) | | |
| | |
As of
December 31, 2020 |
| |
As of
December 31, 2021 |
| ||||||
| | |
(amounts in $ and in
thousands) |
| |||||||||
選定的合併資產負債表數據: | | | | | | | | | | | | | |
Cash
|
| | | $ | 25,618 | | | | | $ | 17,344 | | |
Total assets
|
| | | $ | 25,741 | | | | | $ | 18,348 | | |
Total liabilities
|
| | | $ | 972 | | | | | $ | 1,635 | | |
可轉換優先股合計
|
| | | $ | 31,806 | | | | | $ | 31,806 | | |
Total shareholders’ deficit
|
| | | $ | (7,037) | | | | | $ | (15,093) | | |
總負債、可轉換優先股和股東虧損
|
| | | $ | 25,741 | | | | | $ | 18,348 | | |
| | |
As of December 31, 2021
|
| |||||||||||||||
| | |
Actual
|
| |
Pro forma
|
| |
Pro forma
as adjusted(1) |
| |||||||||
| | |
(除
外,以千美元為單位
用於股票和每股數據) |
| |||||||||||||||
| | | | $ | | | | | $ | | | | | $ | | | |||
可轉換優先股: | | | | | | | | | | | | | | | | | | | |
A系列可轉換優先股,面值0.0001美元;2,377,642股(實際),無授權股份(預計和預計調整後);2,377,642股已發行和已發行股票(實際);無已發行和已發行股份(預計和預計調整後)
|
| | | $ | 8,806 | | | | | | — | | | | | | — | | |
B系列可轉換優先股,面值0.0001美元;5,443,272股(實際),無授權股份(預計和預計調整後);5,443,272股已發行和已發行股票(實際);無已發行和已發行股份(預計和預計調整後)
|
| | | $ | 23,000 | | | | | | — | | | | | | — | | |
可轉換優先股合計
|
| | | $ | 31,806 | | | | | | — | | | | | | — | | |
Shareholders’ deficit: | | | | | | | | | | | | | | | | | | | |
普通股,每股面值0.0001美元;492,179,086股授權股份;10,274,403股已發行和已發行股份(實際);18,095,317股和24,095,317股已發行和已發行股份(預計和預計調整後)
|
| | | | 1 | | | | | | 2 | | | | | | 2 | | |
新增實收資本
|
| | | | 12,325 | | | | | | 44,130 | | | | | | 75,561 | | |
累計其他綜合損失
|
| | | | (196) | | | | | | (196) | | | | | | (196) | | |
Accumulated deficit
|
| | | | (27,223) | | | | | | (27,223) | | | | | | (27,223) | | |
股東權益合計(虧損)
|
| | | | (15,093) | | | | | | 16,713 | | | | | | 48,144 | | |
| | |
Per
Ordinary Share |
| |
Per
ADS |
|
假設首次公開募股價格
|
| |
US$6.00
|
| | US$6.00 | |
截至2021年12月31日的有形賬面淨值
|
| |
US$1.55
|
| | US$1.55 | |
優先股轉換生效後的預計有形賬面淨值
|
| |
US$0.88
|
| | US$0.88 | |
我們的優先股轉換和本次發售生效後的調整後有形賬面淨值的預計值
|
| |
US$2.00
|
| | US$2.00 | |
本次發行中向新投資者攤薄的有形賬面淨值金額
|
| |
US$4.00
|
| | US$4.00 | |
| | |
Ordinary Shares
Purchased |
| |
Total Consideration
|
| |
Average
Price Per Ordinary Share |
| |
Average
Price Per ADS |
| |||||||||||||||
| | |
Number
|
| |
Percent
|
| |
Amount
|
| |
Percent
|
| |||||||||||||||
現有股東
|
| | | | 18,095,317 | | | | | | 75% | | | | US$44,132,000 | | | | | 55% | | | | US$2.44 | | | US$2.44 | |
New investors
|
| | | | 6,000,000 | | | | | | 25% | | | | US$36,000,000 | | | | | 45% | | | | US$6.00 | | | US$6.00 | |
Total
|
| | | | 24,095,317 | | | | | | 100.0% | | | | US$80,132,000 | | | | | 100.0% | | | | | | | | |
| | |
For the Year Ended December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
| | |
(單位:千美元,
除外
每股和每股金額) |
| |||||||||
精選合併經營報表和全面虧損 | | | | | | | | | | | | | |
總運營費用(1)
|
| | | | 5,743 | | | | | | 9,797 | | |
其他(費用)收入總額,淨額
|
| | | | (9) | | | | | | 131 | | |
Net loss
|
| | | | (5,753) | | | | | | (9,666) | | |
全面虧損
|
| | | $ | (5,747) | | | | | $ | (9,818) | | |
計算基本普通股和稀釋普通股時使用的普通股加權平均數
|
| | | | 8,790,397 | | | | | | 9,569,932 | | |
每股普通股基本和攤薄淨虧損
|
| | | | (0.65) | | | | | | (1.01) | | |
| | |
Year Ended
|
| |||||||||
| | |
December 31,
2020 |
| |
December 31,
2021 |
| ||||||
| | |
(amounts in $
and in thousands) |
| |||||||||
研發
|
| | | $ | 77 | | | | | $ | 52 | | |
一般和行政
|
| | | | 1,286 | | | | | | 1,478 | | |
Total
|
| | | $ | 1,363 | | | | | $ | 1,530 | | |
| | |
As of
December 31, 2020 |
| |
As of
December 31, 2021 |
| ||||||
| | |
(amounts in $
and in thousands) |
| |||||||||
選定的合併資產負債表數據: | | | | | | | | | | | | | |
Cash
|
| | | $ | 25,618 | | | | | $ | 17,344 | | |
Total assets
|
| | | $ | 25,741 | | | | | $ | 18,348 | | |
Total liabilities
|
| | | $ | 972 | | | | | $ | 1,635 | | |
可轉換優先股合計
|
| | | $ | 31,806 | | | | | $ | 31,806 | | |
股東虧損總額
|
| | | $ | (7,037) | | | | | $ | (15,093) | | |
總負債、可轉換優先股和股東虧損
|
| | | $ | 25,741 | | | | | $ | 18,348 | | |
| | |
For the Years Ended December 31,
|
| |
Change
|
| | ||||||||||||||||||||
| | |
2020
|
| |
2021
|
| | ||||||||||||||||||||
| | |
(amounts in $ and in thousands)
|
| | | | | | | |
(%)
|
| | ||||||||||||||
Expenses | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
研發(1)
|
| | | | 3,688 | | | | | | 7,419 | | | | | | 3,731 | | | | | | 101.2 | | | | ||
一般和行政(1)
|
| | | | 2,055 | | | | | | 2,378 | | | | | | 323 | | | | | | 15.7 | | | | ||
總運營費用
|
| | | | 5,743 | | | | | | 9,797 | | | | | | 4,054 | | | | | | 70.6 | | | | ||
Loss from operations
|
| | | | (5,743) | | | | | | (9,797) | | | | | | (4,054) | | | | | | 70.6 | | | | ||
Other income (expense): | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Interest income
|
| | | | 12 | | | | | | 5 | | | | | | (7) | | | | | | (58.3) | | | | ||
Interest expense
|
| | | | (21) | | | | | | — | | | | | | 21 | | | | | | 100 | | | | ||
Other income
|
| | | | — | | | | | | 126 | | | | | | 126 | | | | | | | | | | ||
其他(費用)收入總額,淨額
|
| | | | (9) | | | | | | 131 | | | | | | 140 | | | | | | 1,555.6 | | | | ||
Loss before income tax
|
| | | | (5,752) | | | | | | (9,666) | | | | | | (3,914) | | | | | | 168.0 | | | | ||
Income tax expense
|
| | | | (1) | | | | | | — | | | | | | 1 | | | | | | 100 | | | | ||
Net loss
|
| | | | (5,753) | | | | | | (9,666) | | | | | | (3,915) | | | | | | 168.0 | | | | ||
其他綜合收益(虧損) | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
外幣折算調整,扣除零税
|
| | | | 6 | | | | | | (152) | | | | | | (158) | | | | | | (2,633.3) | | | | ||
全面虧損
|
| | | $ | (5,747) | | | | | $ | (9,818) | | | | | $ | (4,071) | | | | | $ | (70.8) | | | |
| | |
Years ended December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
研發
|
| | | $ | 77 | | | | | $ | 52 | | |
一般和行政
|
| | | | 1,286 | | | | | | 1,478 | | |
Total
|
| | | $ | 1,363 | | | | | $ | 1,530 | | |
| | |
For the Years Ended December 31,
|
| |||||||||||||||||||||
(千美元,百分比除外)
|
| |
2020
|
| |
2021
|
| ||||||||||||||||||
| | |
$
|
| |
%
|
| |
$
|
| |
%
|
| ||||||||||||
簽約研究費用和臨牀試驗費用
|
| | | | 1,979 | | | | | | 53.7 | | | | | | 6,384 | | | | | | 86.0 | | |
諮詢費和專業服務費
|
| | | | 319 | | | | | | 8.6 | | | | | | 492 | | | | | | 6.6 | | |
Royalties
|
| | | | 1,187 | | | | | | 32.2 | | | | | | 103 | | | | | | 1.4 | | |
Other expenses
|
| | | | 203 | | | | | | 5.5 | | | | | | 440 | | | | | | 6.0 | | |
Total
|
| | | $ | 3,688 | | | | | | 100 | | | | | $ | 7,419 | | | | | | 100 | | |
| | |
Number of
Options |
| |
Weighted
Average Exercise Price |
| |
Weighted
Average Grant Date Fair Value |
| |
Weighted
Average Remaining Term (Years) |
| |
Aggregate
Intrinsic Value |
| |||||||||||||||
Outstanding as of January 1, 2020
|
| | | | 1,335,794 | | | | | $ | 0.1191 | | | | | $ | 2.4720 | | | | | | 9.96 | | | | | | 3,301 | | |
Granted
|
| | | | 2,807,381 | | | | | $ | 0.4386 | | | | | $ | 2.2574 | | | | | | — | | | | | | — | | |
Exercised
|
| | | | (727,676) | | | | | $ | 0.1191 | | | | | $ | 2.4720 | | | | | | — | | | | | | — | | |
Forfeited or expired
|
| | | | (19,601) | | | | | $ | 0.1191 | | | | | $ | 2.4733 | | | | | | — | | | | | | — | | |
Outstanding as of December 31, 2020
|
| | | | 3,395,898 | | | | | $ | 0.3832 | | | | | $ | 2.2946 | | | | | | 9.80 | | | | | | 7,834 | | |
Granted
|
| | | | 41,736 | | | | | $ | 4.2254 | | | | | $ | 0.4626 | | | | | | — | | | | | | — | | |
Exercised
|
| | | | (706,406) | | | | | $ | 0.3289 | | | | | $ | 2.3311 | | | | | | — | | | | | | — | | |
Forfeited or expired
|
| | | | (748,667) | | | | | $ | 0.4386 | | | | | $ | 2.2574 | | | | | | — | | | | | | — | | |
Outstanding Options, December 31, 2021
|
| | | | 1,982,561 | | | | | $ | 0.4626 | | | | | $ | 2.2571 | | | | | | 8.82 | | | | | $ | 4,480 | | |
截至2021年12月31日,已授予並預計將授予期權
|
| | | | 844,774 | | | | | $ | 0.3935 | | | | | $ | 2.3052 | | | | | | 8.58 | | | | | $ | 1,969 | | |
截至2021年12月31日的可行使期權
|
| | | | 356,067 | | | | | $ | 0.2291 | | | | | $ | 2.4192 | | | | | | 7.99 | | | | | $ | 891 | | |
| | |
As of
December 17, 2019 |
| |
As of
December 23, 2020 |
| |
As of
March 1, 2021 |
| |||||||||
Risk-free interest rate
|
| |
1.72% – 1.74%
|
| | | | 0.51% | | | | | | 0.87% | | | |||
預期波動範圍
|
| |
35.50% – 35.72%
|
| | | | 36.59% | | | | | | 36.75% | | | |||
Exercise multiple
|
| | | | 2.8 | | | | | | 2.8 | | | | | | 2.8 | | |
預期股息收益率
|
| | | | — | | | | | | — | | | | | | — | | |
| | |
Years ended December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
研發
|
| | | $ | 77 | | | | | $ | 52 | | |
一般和行政
|
| | | | 1,286 | | | | | | 1,478 | | |
Total
|
| | | $ | 1,363 | | | | | $ | 1,530 | | |
Indication
|
| |
Clinical Trials
|
| |
Trial Participants
|
| |
Estimated Timeline
|
|
STGD1
|
| |
第一階段單次和多次遞增劑量試驗
|
| |
Healthy adult subjects
|
| |
Completed
|
|
| Phase 1b trial | | | 患有STGD1的青少年患者 | | | Completed | | ||
| Phase 2 trial | | | 患有STGD1的青少年患者 | | | 正在進行中,預計在12個月、15個月、18個月和21個月捕獲臨時數據讀出,並在24個月捕獲最終數據讀出。 | | ||
| Phase 3 trial | | | 患有STGD1的青少年患者 | | | Initiated | | ||
Dry AMD
|
| |
第一階段單次遞增劑量試驗
|
| |
Healthy adult subjects
|
| |
Completed
|
|
| Phase 2 or Phase 3 trial | | | Patients with dry AMD | | | 2022 | |
Adverse Events
|
| |
Severity
|
| |
Relationship
to Drug |
| |
Frequency
(#Patients) |
| |
%
Recovered |
| |
% On-going
|
| |||||||||
黃視/色視
|
| | | | 温和的 | | | |
Definitely Related
|
| | | | 7/11 | | | |
7/7 (100%)
|
| | | | 0/7 | | |
延遲暗適應(DDA)
|
| | | | 温和的 | | | |
Definitely Related
|
| | | | 7/11 | | | |
7/7 (100%)
|
| | | | 0/7 | | |
夜視障礙
|
| | | | 温和的 | | | |
Definitely Related
|
| | | | 1/11 | | | |
1/1 (100%)
|
| | | | 0/1 | | |
Adverse Events
|
| |
Severity
|
| |
Relationship
to Drug |
| |
Frequency
(#Patients) |
| |
%
Recovered |
| |
% On-going
|
| ||||||
黃視/色視
|
| | | | 温和的 | | | |
Definitely Related
|
| | | | 6/13 | | | |
3/6 (50%)
|
| |
3/6 (50%)
|
|
延遲暗適應(DDA)
|
| | | | 温和的 | | | |
Definitely Related
|
| | | | 8/13 | | | |
1/8 (12.5%)
|
| |
7/8 (87.5%)
|
|
夜視障礙
|
| | | | 温和的 | | | |
Definitely Related
|
| | | | 1/13 | | | |
0/1
|
| |
1/1 (100%)
|
|
增加FM100上的錯誤分數
|
| | | | 温和的 | | | |
Probably Related
|
| | | | 1/13 | | | |
0/1
|
| |
1/1 (100%)
|
|
Adverse Events
|
| |
Severity
|
| |
Frequency (#Subjects)
|
|
黃花 - 黃色在色覺上更突出 | | |
Mild
|
| |
1/29
|
|
Adverse Events
|
| |
Severity
|
| |
Frequency (#Subjects)
|
|
延遲暗適應(DDA) | | |
Mild
|
| |
16/24
|
|
Xanthopsia - 黃色在色覺上更突出 | | |
Mild
|
| |
1/24
|
|
畏光 - 對光的敏感度 | | |
Mild
|
| |
1/24
|
|
Ocular migraine | | |
Mild
|
| |
1/24
|
|
間歇性消化不良(消化不良) | | |
Mild
|
| |
1/24
|
|
Migraine | | |
Moderate
|
| |
1/24
|
|
Patent
Family No. |
| |
Type of Patent
|
| |
Issued Countries/ Regions
and/or Application Type |
| |
Pending
Countries/ Regions and/or Application Type |
| |
Termination Date
(mm/dd/yyyy) |
| |
Subject to
“March-in Rights” (Yes/ No) |
|
1 | | | Utility – Methods of Use | | |
U.S
Europe Japan |
| | N.A | | | 11/22/2031 | | | Yes | |
2 | | | Utility – Methods of Use | | | U.S | | | N.A | | | 04/30/2033 | | | Yes | |
3 | | | 公用事業 - 製造和物質組成 | | |
U.S
U.S Divisional #1 Europe Europe Divisional |
| |
U.S Divisional #2
Hong Kong |
| | 03/13/2034 | | | Yes | |
4 | | | 公用事業 - 製造和物質組成 | | |
U.S
U.S Continuation #1 U.S Continuation #2 Europe |
| | N.A | | | 03/13/2034 | | | Yes | |
5 | | | 公用事業 - 製造和物質組成 | | |
U.S
U.S Divisional |
| | N.A | | | 03/13/2034 | | | Yes | |
6 | | | 公用事業 - 製造和物質組成 | | |
U.S
U.S Continuation |
| | N.A | | | 03/13/2034 | | | Yes | |
7 | | |
Utility – Manufacture
和物質的組成 |
| |
U.S
U.S Continuation #1 美國續集#2美國續集#3 U.S Continuation #4 Europe Australia India Mexico Japan Philippines China Singapore Indonesia |
| |
U.S Continuation
#5 Hong Kong South Korea Myanmar Thailand Canada China Divisional New Zealand Brazil Europe Divisional |
| | 04/29/2035 | | | Yes | |
8 | | | Utility – Methods of Use | | | N.A | | |
U.S
Europe Hong Kong China |
| | 08/01/2039 | | | Yes | |
Patent
Family No. |
| |
Type of Patent
|
| |
Issued Countries/
Regions and/or Application Type |
| |
Pending
Countries/ Regions and/or Application Type |
| |
Termination
Date (mm/dd/yyyy) |
| |
Subject to
“March-in Rights” (Yes/ No) |
|
9 | | |
Utility – Methods of
Use |
| |
U.S,
U.S Divisional #1 |
| |
U.S Divisional #2
Europe Taiwan Hong Kong |
| | 06/14/2038 | | | No | |
Patent
Family No. |
| |
Type of Patent
|
| |
Issued Countries/
Regions and/or Application Type |
| |
Pending
Countries/ Regions and/or Application Type |
| |
Expected
Termination Date (mm/dd/yyyy) |
| |
Subject to
“March-in Rights” (Yes/ No) |
|
10 | | |
Utility – Methods of
Use |
| | N.A | | |
Europe
Taiwan Hong Kong |
| | 06/14/2038 | | | No | |
11 | | | Utility – Formulations | | | N.A | | |
U.S
Europe Australia Canada China India Israel Japan South Korea Singapore Taiwan |
| | 07/06/2040 | | | No | |
12 | | | 實用程序 - 輔助診斷 | | | N.A | | | U.S Provisional | | | 05/21/2042 | | | No | |
13 | | | Utility – Formulation | | | N.A | | | U.S Provisional | | | 11/23/2042 | | | No | |
14 | | |
Utility – Assessing
Visual Function |
| | N.A | | | U.S Provisional | | | 04/14/2043 | | | No | |
Functions
|
| |
Number of
Employees |
| |
% of Total
|
| ||||||
Finance and Accounting
|
| | | | 5 | | | | | | 42% | | |
研究與開發
|
| | | | 7 | | | | | | 58% | | |
Total | | | | | 12 | | | | | | 100% | | |
Name
|
| |
Age
|
| |
Positions(s)
|
|
Yu-Hsin Lin | | |
44
|
| | 首席執行官兼董事會主席* | |
Hao-Yuan Chuang | | |
38
|
| | 董事首席財務官* | |
Nathan L. Mata | | |
56
|
| | 首席科學官 | |
Ching-Chen Chiu | | |
52
|
| |
臨牀運營副總裁
|
|
Wan-Shan Chen | | |
36
|
| | Director* | |
Hung-Wei Chen | | |
40
|
| | Director* | |
John M. Longo | | |
53
|
| | 獨立董事提名者# | |
Ita Lu | | |
45
|
| | 獨立董事提名者# | |
Gary C. Biddle | | |
70
|
| | 獨立董事提名者# | |
Name
|
| |
Ordinary
Shares Underlying Options |
| |
Exercise
Price (US$/Share) |
| |
Date of Grant
|
| |
Date of Expiration
|
| ||||||
Yu-Hsin Lin
|
| | | | 827,814 | | | | | $ | 0.4386 | | | |
December 23, 2020
|
| |
December 22, 2030
|
|
| | | | | * | | | | | $ | 6.00(1) | | | |
April 18, 2022#
|
| |
##
|
|
Hao-Yuan Chuang
|
| | | | 579,471 | | | | | $ | 0.4386 | | | |
December 23, 2020
|
| |
December 22, 2030
|
|
| | | | | * | | | | | $ | 6.00(1) | | | |
April 18, 2022#
|
| |
##
|
|
Nathan L. Mata
|
| | | | 748,667 | | | | | $ | 6.00(1) | | | |
April 18, 2022#
|
| |
##
|
|
Ching-Chen Chiu
|
| | | | 350,000 | | | | | $ | 6.00(1) | | | |
April 18, 2022#
|
| |
##
|
|
Wan-Shan Chen
|
| | | | * | | | | | $ | 0.4386 | | | |
December 23, 2020
|
| |
December 22, 2030
|
|
Hung-Wei Chen
|
| | | | * | | | | | $ | 0.4386 | | | |
December 23, 2020
|
| |
December 22, 2030
|
|
John M. Longo
|
| | | | * | | | | | $ | 6.00(1) | | | |
April 18, 2022#
|
| |
##
|
|
Gary C. Biddle
|
| | | | * | | | | | $ | 6.00(1) | | | |
April 18, 2022#
|
| |
##
|
|
所有董事和高管
a group |
| | |
|
2,853,442
|
| | | | | | | | | | | | | |
| | |
普通股受益
在本次發行之前擁有 |
| |
實益擁有的普通股
After This Offering |
| ||||||||||||||||||||||||
| | |
Ordinary
Shares |
| |
% of
Beneficial Ownership† |
| |
Ordinary
Shares |
| |
% of
Beneficial Ownership |
| |
% of
aggregate voting power†† |
| |||||||||||||||
董事和高管**: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Yu-Hsin Lin(1)
|
| | | | 2,463,015 | | | | | | 13.61% | | | | | | 2,773,758 | | | | | | 11.51% | | | | | | 11.51% | | |
Hao-Yuan Chuang(2)
|
| | | | 529,193 | | | | | | 2.92% | | | | | | 532,241 | | | | | | 2.21% | | | | | | 2.21% | | |
Nathan L. Mata
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Ching-Chen Chiu
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
Wan-Shan Chen(3)
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
Hung-Wei Chen(4)
|
| | | | 193,526 | | | | | | 1.07% | | | | | | * | | | | | | * | | | | | | * | | |
約翰·M·隆戈(獨立董事提名人)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
伊塔魯(獨立董事提名者)(5)。
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
加里·C·比德爾(獨立董事提名人)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
主要股東: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
林氏生物科學國際有限公司(6)。
|
| | | | 13,928,597 | | | | | | 76.97% | | | | | | 16,428,597 | | | | | | 68.18% | | | | | | 68.18% | | |
Securities/Purchaser
|
| |
Date of Issuance
|
| |
Number of Securities
|
| |
Exercise
Price |
| |||
Options | | | | | | | | | | | | | |
某些董事、高級管理人員和員工
|
| |
December 17, 2019
|
| |
購買最多1,335,794股普通股的選擇權
|
| | | $ | 0.1191 | | |
某些董事、高級管理人員和員工
|
| |
December 23, 2020
|
| |
購買最多2,807,381股普通股的選擇權
|
| | | $ | 0.4386(1) | | |
某些關鍵顧問
|
| |
March 1, 2021
|
| |
購買最多41,736股普通股的選擇權
|
| | | $ | 4.2254 | | |
某些董事、高級管理人員和員工
|
| |
April 18, 2022#
|
| |
購買最多1,698,667股普通股的選擇權
|
| | | $ | 6.00(2) | | |
Service
|
| |
Fees
|
|
·任何獲發美國存託憑證的人或任何根據股票股息或其他免費股票分配、紅利分配、股票拆分或其他分配(轉換為現金的除外)就美國存托股份分配而獲得分配的人 | | | Up to US$0.05 per ADS issued | |
·取消美國存託憑證,包括終止存款協議的情況 | | | Up to US$0.05 per ADS cancelled | |
·現金股利分配 | | | Up to US$0.05 per ADS held | |
·出售權利、證券和其他權利的現金權利(現金股息除外)和/或現金收益的分配 | | | Up to US$0.05 per ADS held | |
·根據行使權利分配美國存託憑證。 | | | Up to US$0.05 per ADS held | |
·發行美國存託憑證以外的證券或購買額外美國存託憑證的權利 | | | Up to US$0.05 per ADS held | |
• Depositary services | | | 在開户銀行建立的適用記錄日期持有的美國存托股份最高可達0.05美元 | |
If we:
|
| |
Then:
|
|
更改我們普通股的面值或面值 | | | 託管人收到的現金、股票或其他證券將成為存款證券。 | |
對任何存放的證券進行重新分類、拆分或合併 | | | 每個美國存托股份將自動代表其在新存入的證券中所佔的平均份額。 | |
在未分配給您的普通股上分配證券,或
資本重組、重組、合併、清算、出售我們的全部或幾乎所有資產,或採取任何類似行動 |
| | 託管人可以將其收到的部分或全部現金、股票或其他證券進行分配。它還可能提供新的美國存託憑證或要求您交出未償還的美國存託憑證,以換取識別新存入證券的新的美國存託憑證。 | |
Name
|
| |
Number of ADSs
|
| |||
The Benchmark Company,LLC
|
| | | | 6,000,000 | | |
Total
|
| | | | 6,000,000 | | |
| | |
Total
|
| |||||||||||||||
| | |
Per ADS
|
| |
No Exercise
|
| |
Full exercise
|
| |||||||||
Public offering price
|
| | | 美元 | | | | | | 美元 | | | | | 美元 | | | ||
承保折扣和佣金(1)
|
| | | 美元 | | | | | | 美元 | | | | | 美元 | | | ||
未扣除費用的收益給我們
|
| | | 美元 | | | | | | 美元 | | | | | 美元 | | | |
|
SEC Registration Fee
|
| | | 美元 | 4,000 | | |
|
FINRA Filing Fee
|
| | | | 8,000 | | |
|
證券交易所入市和上市費
|
| | | | 75,000 | | |
|
印刷費和雕刻費
|
| | | | 126,000 | | |
|
Legal Fees and Expenses
|
| | | | 1,697,000 | | |
|
會計費和費用
|
| | | | 84,000 | | |
|
Miscellaneous
|
| | | | 155,000 | | |
| Total | | | | 美元 | 2,149,000 | | |
| | |
PAGE(S)
|
| |||
獨立註冊會計師事務所報告
|
| | | | F-2 | | |
截至2020年12月31日和2021年12月31日的合併資產負債表
|
| | | | F-3 | | |
截至2020年12月31日和2021年12月31日的年度綜合經營報表和全面虧損
|
| | | | F-4 | | |
截至2020年12月31日和2021年12月31日的年度可轉換優先股和股東虧損合併報表
|
| | | | F-5 | | |
截至2020年12月31日和2021年12月31日的年度合併現金流量表
|
| | | | F-6 | | |
合併財務報表附註
|
| | | | F-7 | | |
| | |
December 31
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
ASSETS | | | | ||||||||||
Current Assets
Cash |
| | | $ | 25,618 | | | | | $ | 17,344 | | |
預付款和其他流動資產
|
| | | | 50 | | | | | | 87 | | |
Total current assets
|
| | | | 25,668 | | | | | | 17,431 | | |
財產和設備,淨額
|
| | | | 46 | | | | | | 94 | | |
物業和設備預付款
|
| | | | 20 | | | | | | — | | |
延期發售成本
|
| | | | — | | | | | | 815 | | |
Security deposits
|
| | | | 7 | | | | | | 8 | | |
TOTAL ASSETS
|
| | | $ | 25,741 | | | | | $ | 18,348 | | |
負債、可轉換優先股和股東虧損
|
| | | ||||||||||
流動負債 | | | | | | | | | | | | | |
應付關聯方的其他款項
|
| | | $ | 26 | | | | | $ | 71 | | |
應計費用和其他負債
|
| | | | 946 | | | | | | 1,564 | | |
流動負債總額
|
| | | | 972 | | | | | | 1,635 | | |
TOTAL LIABILITIES
|
| | | | 972 | | | | | | 1,635 | | |
承付款和或有事項 | | | | | | | | | | | | | |
可轉換優先股 | | | | | | | | | | | | | |
截至2020年12月31日和2021年12月31日,A系列可轉換優先股,面值0.0001美元,授權、已發行和已發行股票2,377,642股
|
| | | | 8,806 | | | | | | 8,806 | | |
截至2020年12月31日和2021年12月31日,B系列可轉換優先股,面值0.0001美元,授權、發行和發行的股票5,443,272股
|
| | | | 23,000 | | | | | | 23,000 | | |
可轉換優先股合計
|
| | | | 31,806 | | | | | | 31,806 | | |
股東虧損 | | | | | | | | | | | | | |
普通股,每股票面價值0.0001美元;492,179,086股授權股份;
9,567,997 and 10,274,403 shares issued and outstanding as of December 31, 2020 and 2021, respectively |
| | | | 1 | | | | | | 1 | | |
新增實收資本
|
| | | | 10,563 | | | | | | 12,325 | | |
累計其他綜合損失
|
| | | | (44) | | | | | | (196) | | |
Accumulated deficit
|
| | | | (17,557) | | | | | | (27,223) | | |
股東虧損總額
|
| | | | (7,037) | | | | | | (15,093) | | |
總負債、可轉換優先股和股東虧損
|
| | | $ | 25,741 | | | | | $ | 18,348 | | |
| | |
For the Years Ended
December 31, |
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Expenses | | | | | | | | | | | | | |
研發
|
| | | | 3,688 | | | | | | 7,419 | | |
一般和行政
|
| | | | 2,055 | | | | | | 2,378 | | |
總運營費用
|
| | | | 5,743 | | | | | | 9,797 | | |
Loss from operations
|
| | | | (5,743) | | | | | | (9,797) | | |
Other income (expense): | | | | | | | | | | | | | |
Interest income
|
| | | | 12 | | | | | | 5 | | |
Interest expense
|
| | | | (21) | | | | | | — | | |
Other income
|
| | | | — | | | | | | 126 | | |
其他(費用)收入總額,淨額
|
| | | | (9) | | | | | | 131 | | |
Loss before income tax
|
| | | | (5,752) | | | | | | (9,666) | | |
Income tax expense
|
| | | | (1) | | | | | | — | | |
Net loss
|
| | | | (5,753) | | | | | | (9,666) | | |
其他綜合收益(虧損) | | | | | | | | | | | | | |
外幣折算調整,扣除零税
|
| | | | 6 | | | | | | (152) | | |
全面虧損
|
| | | $ | (5,747) | | | | | $ | (9,818) | | |
計算中使用的普通股加權平均數: | | | | | | | | | | | | | |
− Basic and Diluted
|
| | | | 8,790,397 | | | | | | 9,569,932 | | |
每股普通股淨虧損
|
| | | | | | | | | | | | |
− Basic and Diluted
|
| | | $ | (0.65) | | | | | $ | (1.01) | | |
| | |
Convertible Preferred
Shares |
| | |
Ordinary Shares
|
| |
Additional
Paid-in Capital |
| |
Accumulated
other Comprehensive loss |
| |
Accumulated
deficit |
| |
Total
Shareholders’ deficit |
| ||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2020
|
| | | | — | | | | | $ | — | | | | | | | 7,840,321 | | | | | $ | 1 | | | | | $ | 8,114 | | | | | $ | (50) | | | | | $ | (11,804) | | | | | $ | (3,739) | | |
普通股發行
|
| | | | — | | | | | | — | | | | | | | 500,000 | | | | | | — | | | | | | 500 | | | | | | — | | | | | | — | | | | | | 500 | | |
應付關聯方其他應付款項轉換後發行普通股
|
| | | | — | | | | | | — | | | | | | | 500,000 | | | | | | — | | | | | | 500 | | | | | | — | | | | | | — | | | | | | 500 | | |
發行A系列優先股
|
| | | | 1,833,892 | | | | | | 6,792 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
轉換可轉換本票後發行A系列優先股
|
| | | | 543,750 | | | | | | 2,014 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
發行B系列優先股
|
| | | | 5,443,272 | | | | | | 23,000 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
行使股票期權
|
| | | | — | | | | | | — | | | | | | | 727,676 | | | | | | — | | | | | | 86 | | | | | | — | | | | | | — | | | | | | 86 | | |
基於股份的薪酬費用
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 1,363 | | | | | | — | | | | | | — | | | | | | 1,363 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (5,753) | | | | | | (5,753) | | |
外幣折算調整
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | 6 | | | | | | — | | | | | | 6 | | |
Balance as of December 31, 2020
|
| | | | 7,820,914 | | | | | $ | 31,806 | | | | | | | 9,567,997 | | | | | $ | 1 | | | | | $ | 10,563 | | | | | $ | (44) | | | | | $ | (17,557) | | | | | $ | (7,037) | | |
行使股票期權
|
| | | | — | | | | | | — | | | | | | | 706,406 | | | | | | — | | | | | | 232 | | | | | | — | | | | | | — | | | | | | 232 | | |
基於股份的薪酬費用
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 1,530 | | | | | | — | | | | | | — | | | | | | 1,530 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (9,666) | | | | | | (9,666) | | |
外幣折算調整
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | (152) | | | | | | — | | | | | | (152) | | |
Balance as of December 31, 2021
|
| | | | 7,820,914 | | | | | $ | 31,806 | | | | | | | 10,274,403 | | | | | $ | 1 | | | | | $ | 12,325 | | | | | $ | (196) | | | | | $ | (27,223) | | | | | $ | (15,093) | | |
| | |
For the years ended
December 31, |
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
經營活動產生的現金流 | | | | | | | | | | | | | |
Net loss
|
| | | $ | (5,753) | | | | | $ | (9,666) | | |
將淨虧損與經營活動中使用的現金淨額進行調整: | | | | | | | | | | | | | |
Depreciation
|
| | | | 17 | | | | | | 30 | | |
基於股份的薪酬費用
|
| | | | 1,363 | | | | | | 1,530 | | |
處置財產和設備的收益
|
| | | | — | | | | | | (8) | | |
經營性資產和負債變動:
|
| | | | | | | | | | | | |
關聯方其他應收賬款
|
| | | | 4 | | | | | | — | | |
Prepayments
|
| | | | 192 | | | | | | (35) | | |
應付關聯方的其他應付款
|
| | | | (19) | | | | | | 45 | | |
應計費用和其他負債
|
| | | | (254) | | | | | | 632 | | |
Security deposits
|
| | | | 8 | | | | | | (2) | | |
經營活動中使用的淨現金
|
| | | | (4,442) | | | | | | (7,474) | | |
投資活動產生的現金流 | | | | | | | | | | | | | |
購置財產和設備
|
| | | | — | | | | | | (74) | | |
物業和設備預付款
|
| | | | (20) | | | | | | — | | |
處置財產和設備的收益
|
| | | | — | | | | | | 18 | | |
投資活動中使用的淨現金
|
| | | | (20) | | | | | | (56) | | |
融資活動產生的現金流 | | | | | | | | | | | | | |
延期發行費用的支付
|
| | | | — | | | | | | (815) | | |
關聯方貸款收益
|
| | | | 131 | | | | | | — | | |
償還關聯方貸款
|
| | | | (2,450) | | | | | | — | | |
發行普通股所得收益
|
| | | | 500 | | | | | | — | | |
發行可轉換優先股
|
| | | | 29,792 | | | | | | — | | |
從行使股票期權開始
|
| | | | 86 | | | | | | 232 | | |
用於融資活動的現金淨額
|
| | | | 28,059 | | | | | | (583) | | |
匯率對現金的影響
|
| | | | 4 | | | | | | (161) | | |
現金淨(減)增
|
| | | | 23,601 | | | | | | (8,274) | | |
年初的現金
|
| | | | 2,017 | | | | | | 25,618 | | |
CASH AT END OF THE PERIOD
|
| | | $ | 25,618 | | | | | $ | 17,344 | | |
補充披露現金流量信息 | | | | | | | | | | | | | |
Interest paid
|
| | | | 19 | | | | | | — | | |
非現金投資補充披露 | | | | | | | | | | | | | |
可轉換本票和應計利息轉換為可轉換優先股
|
| | | | 2,014 | | | | | | — | | |
將其他應付關聯方款項轉換為普通股
|
| | | | 500 | | | | | | — | | |
Subsidiaries
|
| |
Date of
incorporation |
| |
Place of
incorporation |
| |
Ownership
|
| |
Principal
activities |
|
Belite Bio Holdings Corp.
(“Belite Holding”) |
| | June 10, 2016 | | |
美利堅合眾國
|
| | 100% owned by Belite | | | Investment holding | |
Belite Bio, LLC
(“Belite USA”) |
| | June 10, 2016 | | |
美利堅合眾國
|
| |
100% owned by Belite Holding
|
| |
研發
|
|
RBP4 Pty Ltd
(“RBP4”) |
| | August 13, 2018 | | | Australia | | |
100% owned by Belite Holding
|
| | 臨牀試驗活動 | |
Belite Bio (HK) Limited
(“Belite HK”) |
| | June 10, 2021 | | | Hong Kong | | | 100% owned by Belite | | | Investment holding | |
貝利特生物(上海)有限公司
(“Belite Shanghai”) |
| | August 12, 2021 | | | China | | | 100% owned by Belite HK | | | 臨牀試驗活動 | |
Supplier
|
| |
2020
|
| |
2021
|
| ||||||
A | | | | $ | * | | | | | $ | 2,385 | | |
B | | | | | * | | | | | | 1,213 | | |
C | | | | | 776 | | | | | | 765 | | |
D | | | | | 1,187 | | | | | | * | | |
E | | | | | 448 | | | | | | * | | |
F | | | | | 442 | | | | | | * | | |
G | | | | | 423 | | | | | | * | | |
| | |
As of December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
Prepayments | | | | | | | | | | | | | | | ||
其他服務的−預付款
|
| | | $ | 10 | | | | | $ | 64 | | | | ||
可抵扣增值税進項
|
| | | | 40 | | | | | | 23 | | | | ||
| | | | $ | 50 | | | | | $ | 87 | | | |
| | |
As of December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
Laboratory equipment
|
| | | $ | 92 | | | | | $ | 141 | | | | ||
減去:累計折舊
|
| | | | (46) | | | | | | (47) | | | | ||
Total
|
| | | $ | 46 | | | | | $ | 94 | | | |
| | |
As of December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
研發
|
| | | $ | 488 | | | | | $ | 741 | | | | ||
Legal and consulting
|
| | | | 266 | | | | | | 525 | | | | ||
License royalties
|
| | | | 187 | | | | | | 147 | | | | ||
Other
|
| | | | 5 | | | | | | 151 | | | | ||
| | | | $ | 946 | | | | | $ | 1,564 | | | |
| | |
December 31, 2020 and 2021
|
| | | | | | | | | | | | | |||||||||||||||||||||||||||
| | |
Preferred
Shares Authorized |
| |
Preferred
Shares Issued and Outstanding |
| |
Carrying
Value |
| |
Liquidation
Value |
| |
Common
Stock Issuable Upon Conversion |
| | | | | |||||||||||||||||||||||
A系列優先股
|
| | | | 2,377,642 | | | | | $ | 2,377,642 | | | | | $ | 8,806 | | | | | $ | 8,806 | | | | | | 2,377,642 | | | | | | | ||||||||
B系列優先股
|
| | | | 5,443,272 | | | | | | 5,443,272 | | | | | | 23,000 | | | | | | 23,000 | | | | | | 5,443,272 | | | | | | | ||||||||
Total
|
| | | | 7,820,914 | | | | | | 7,820,914 | | | | | | 31,806 | | | | | | 31,806 | | | | | | 7,820,914 | | | | | | |
| | |
As of December 17,
2019 |
| |
As of December 23,
2020 |
| |
As of March 1,
2021 |
|
Risk-free interest rate
|
| |
1.72% – 1.74%
|
| |
0.51%
|
| |
0.87%
|
|
預期波動範圍
|
| |
35.50% – 35.72%
|
| |
36.59%
|
| |
36.75%
|
|
Exercise multiple
|
| |
2.8
|
| |
2.8
|
| |
2.8
|
|
預期股息收益率
|
| |
—
|
| |
—
|
| |
—
|
|
| | |
Number of
Options |
| |
Weighted
Average Exercise Price |
| |
Weighted
Average Grant Date Fair Value |
| |
Weighted
Average Remaining Term (Years) |
| |
Aggregate
Intrinsic Value |
| |||||||||||||||
Outstanding as of January 1, 2020
|
| | | | 1,335,794 | | | | | $ | 0.1191 | | | | | $ | 2.4720 | | | | | | 9.96 | | | | | | 3,301 | | |
Granted
|
| | | | 2,807,381 | | | | | $ | 0.4386 | | | | | $ | 2.2574 | | | | | | — | | | | | | — | | |
Exercised
|
| | | | (727,676) | | | | | $ | 0.1191 | | | | | $ | 2.4720 | | | | | | — | | | | | | — | | |
Forfeited or expired
|
| | | | (19,601) | | | | | $ | 0.1191 | | | | | $ | 2.4733 | | | | | | — | | | | | | — | | |
Outstanding as of December 31, 2020
|
| | | | 3,395,898 | | | | | $ | 0.3832 | | | | | $ | 2.2946 | | | | | | 9.80 | | | | | | 7,834 | | |
Granted
|
| | | | 41,736 | | | | | $ | 4.2254 | | | | | $ | 0.4626 | | | | | | — | | | | | | — | | |
Exercised
|
| | | | (706,406) | | | | | $ | 0.3289 | | | | | $ | 2.3311 | | | | | | — | | | | | | — | | |
Forfeited or expired
|
| | | | (748,667) | | | | | $ | 0.4386 | | | | | $ | 2.2574 | | | | | | — | | | | | | — | | |
Outstanding Options, December 31, 2021
|
| | | | 1,982,561 | | | | | $ | 0.4626 | | | | | $ | 2.2571 | | | | | | 8.82 | | | | | $ | 4,480 | | |
截至2021年12月31日已授予並預計將授予期權
|
| | | | 844,774 | | | | | $ | 0.3935 | | | | | $ | 2.3052 | | | | | | 8.58 | | | | | $ | 1,969 | | |
截至2021年12月31日的可行使期權
|
| | | | 356,067 | | | | | $ | 0.2291 | | | | | $ | 2.4192 | | | | | | 7.99 | | | | | $ | 891 | | |
| | |
Years ended December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
研發
|
| | | $ | 77 | | | | | $ | 52 | | | | ||
一般和行政
|
| | | | 1,286 | | | | | | 1,478 | | | | ||
Total | | | | $ | 1,363 | | | | | $ | 1,530 | | | |
| | |
(In Thousands)
Years ended December 31, |
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
聯邦法定税率
|
| | | | 21% | | | | | | 21% | | | | ||
State taxes
|
| | | | 8.84% | | | | | | 8.84% | | | | ||
Withholding tax
|
| | | | 0.02% | | | | | | 0.00% | | | | ||
研發信用
|
| | | | (0.03)% | | | | | | (0.33)% | | | | ||
不可扣除的費用
|
| | | | (0.27)% | | | | | | (0.20)% | | | | ||
估值免税額的變化
|
| | | | (29.54)% | | | | | | (29.31)% | | | | ||
Effective tax rate
|
| | | $ | 0.02% | | | | | $ | 0.00% | | | |
| | |
As of December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
遞延所得税資產 | | | | | | | | | | | | | | | ||
研發學分
|
| | | $ | 59 | | | | | $ | 103 | | | | ||
淨營業虧損結轉
|
| | | | 3,687 | | | | | | 4,005 | | | | ||
| | | | | 3,746 | | | | | | 4,108 | | | | ||
Valuation allowance
|
| | | | (3,746) | | | | | | (4,108) | | | | ||
遞延所得税淨資產總額
|
| | | $ | — | | | | | $ | — | | | |
| | |
Years ended December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
Numerator: | | | | | | | | | | | | | | | ||
普通股股東應佔淨虧損
|
| | | $ | (5,753) | | | | | $ | (9,666) | | | | ||
Denominator: | | | | | | | | | | | | | | | ||
已發行普通股加權平均數 - 基本股和稀釋股
|
| | | | 8,790,397 | | | | | | 9,569,932 | | | | ||
每股淨虧損 - 基本股和攤薄股
|
| | | $ | (0.65) | | | | | $ | (1.01) | | | |
| | |
Years ended December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
可轉換優先股
|
| | | | 7,820,914 | | | | | | 7,820,914 | | | | ||
未償還股票期權
|
| | | | 3,395,898 | | | | | | 1,982,561 | | | | ||
Total
|
| | | | 11,216,812 | | | | | | 9,803,475 | | | |
Name of related parties
|
| |
與公司的關係
|
|
Lin BioScience, Inc. | | | 公司的最終股東 | |
林生物科學國際有限公司 | | | 公司股東 | |
林生物科學私人有限公司 | | | 由公司最終股東控制 | |
| | |
As of December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
因關聯方原因 | | | | | | | | | | | | | | | ||
Lin BioScience, Inc.
|
| | | $ | 26 | | | | | $ | 71 | | | |
| | |
Years ended December 31,
|
| | | | |||||||||
| | |
2020
|
| |
2021
|
| | ||||||||
Lin BioScience, Inc.: | | | | | | | | | | | | | | | ||
研發費用
|
| | | $ | — | | | | | $ | 183 | | | | ||
專業服務費
|
| | | $ | 21 | | | | | $ | — | | | | ||
Interest Expense
|
| | | $ | 17 | | | | | $ | — | | | |
Securities/Purchaser
|
| |
Date of Issuance
|
| |
Number of Securities
|
| |
Exercise Price
|
|
Options | | | | | | | | | | |
某些董事、高級管理人員和員工 | | |
December 17, 2019
|
| |
Option to purchase up
to 1,335,794 ordinary shares |
| |
$0.1191
|
|
某些董事、高級管理人員和員工 | | |
December 23, 2020
|
| |
Option to purchase up
to 2,807,381 ordinary shares |
| |
$0.4386(1)
|
|
某些關鍵顧問 | | |
March 1, 2021
|
| |
Option to purchase up
to 41,736 ordinary shares |
| |
$4.2254
|
|
Securities/Purchaser
|
| |
Date of Issuance
|
| |
Number of Securities
|
| |
Exercise Price
|
|
某些董事、高級管理人員和員工 | | |
April 18, 2022#
|
| |
Option to purchase up to 1,698,667 ordinary
shares |
| |
$6.00(2)
|
|
|
Exhibit
Number |
| |
Description of Document
|
|
| 1.1† | | |
承保協議格式
|
|
| 3.1† | | |
目前有效的第二次修訂和重新修訂的註冊人組織備忘錄和章程(於2021年11月1日修訂)
|
|
| 3.2† | | |
第三次修訂和重新修訂的註冊人組織備忘錄和章程(在本次發行完成後立即生效)
|
|
| 4.1† | | | 註冊人美國存託憑證樣本(附於附件4.3) | |
| 4.2† | | |
普通股註冊人證書範本
|
|
| 4.3† | | |
根據其發行的美國存托股份的登記人、存託人、持有人和實益所有人之間的存託協議格式
|
|
| 4.4† | | |
由Belite Bio,Inc.和其中點名的Belite Bio,Inc.股東於2020年12月23日修訂並重新簽署的股東協議
|
|
| 4.5† | | |
由Belite Bio,Inc.和其中指名的Belite Bio,Inc.股東之間修訂和重新簽署的股東協議修正案日期為2021年11月1日
|
|
| 5.1† | | |
Maples and Calder(Hong Kong)LLP對正在登記的普通股的有效性和開曼羣島的某些税務問題的意見
|
|
| 8.1† | | |
Maples and Calder(Hong Kong)LLP對開曼羣島某些税務問題的意見(見附件5.1)
|
|
| 8.2† | | |
O‘Melveny&Myers LLP對某些美國税務問題的意見
|
|
| 10.1† | | |
Belite Bio,Inc.修訂並重新啟動股票激勵計劃
|
|
| 10.2† | | |
2022 Performance Incentive Plan
|
|
| 10.3† | | |
註冊人與其高級管理人員之間的僱傭協議格式
|
|
| 10.4† | | |
註冊人與其董事和高管之間的賠償協議格式
|
|
| 10.5† | | |
Belite Bio,Inc.與其中指定的Belite Bio,Inc.某些投資者簽訂的A系列優先股購買和票據轉換協議,日期為2020年1月21日
|
|
| 10.6† | | |
Belite Bio,Inc.與其中指定的Belite Bio,Inc.某些投資者之間簽訂的B系列優先股購買協議,日期為2020年12月23日
|
|
| 10.7#† | | |
Belite Bio,Inc.與紐約市哥倫比亞大學董事會簽訂的獨家許可協議,日期為2016年9月13日
|
|
| 10.8† | | |
Belite Bio,Inc.與紐約市哥倫比亞大學受託人之間的獨家許可協議修正案,日期為2017年8月15日
|
|
| 10.9† | | |
紐約市哥倫比亞大學董事會於2018年5月3日簽發的同意書
|
|
| 10.10#† | | |
2019年3月27日Belite Bio,Inc.與紐約市哥倫比亞大學受託人簽署的獨家許可協議第二修正案
|
|
| 10.11#† | | |
2019年10月24日Belite Bio,Inc.與紐約市哥倫比亞大學受託人簽署的獨家許可協議第三修正案
|
|
| 10.12#† | | |
2021年9月1日,Belite Bio,Inc.與紐約市哥倫比亞大學受託人之間達成的獨家許可協議第四修正案
|
|
| 10.13#† | | |
2022年2月4日由Belite Bio,Inc.與紐約市哥倫比亞大學受託人簽署的《獨家許可協議第五修正案》
|
|
| 10.14† | | |
Belite Bio,Inc.和Lin BioScience,Inc.簽訂的LBS-008研發服務協議,日期為2021年7月1日
|
|
|
Exhibit
Number |
| |
Description of Document
|
|
| 10.15† | | |
Belite Bio,Inc.和Lin BioScience,Inc.於2022年2月23日簽署的LBS-008研發服務協議第一修正案
|
|
| 21.1† | | |
註冊人重要子公司名單
|
|
| 23.1 | | |
Consent of Friedman LLP
|
|
| 23.2† | | | Maples and Calder(Hong Kong)LLP同意(見附件5.1) | |
| 23.3† | | |
商務金融律師事務所同意
|
|
| 24.1† | | |
授權書(包括在簽名頁上)
|
|
| 99.1† | | |
《商業行為和道德準則》(緊接本次發售完成前生效)
|
|
| 99.2† | | |
商務金融律師事務所對某些中國法律問題的意見
|
|
| 99.3† | | |
Consent of John M. Longo
|
|
| 99.4† | | |
Consent of Ita Lu
|
|
| 99.5† | | |
Consent of Gary C. Biddle
|
|
| 107† | | |
Filing Fee Table
|
|
| | | | BELITE BIO, INC | | |||
| | | | By: | | |
/s/ Yu-Hsin Lin
Name: Yu-Hsin Lin
職務: 首席執行官兼董事長 |
|
|
Signature
|
| |
Title
|
|
|
/s/ Yu-Hsin Lin
Name: Yu-Hsin Lin
|
| | 首席執行官、董事會主席(首席執行官) | |
|
/s/ Wan-Shan Chen
Name: Wan-Shan Chen
|
| | Director | |
|
/s/ Hung-Wei Chen
Name: Hung-Wei Chen
|
| | Director | |
|
/s/ Hao-Yuan Chuang
Name: Hao-Yuan Chuang
|
| | 董事首席財務官(首席財務會計官) | |
| | | | 授權的美國代表 | | |||
| | | | By: | | |
/s/ Donald J. Puglisi
Name: Donald J. Puglisi
標題:管理董事 |
|